Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™  in Ménière’s disease Broadest pipeline in neurotology field expanded to include gene therapy collaboration targeting most common cause of congenital hearing loss Current capital funds operations into 2021

Apply Now